International Journal of Radiation Oncology Biology Physics最新文献

{"title":"Analysis of the Radiosensitivity Index (RSI) in Paired Pre- and Post-Neoadjuvant Therapy Triple-Negative Breast Cancer.","authors":"Shane R Stecklein, Roberto Salgado, Julia R White, Bruce F Kimler, Rachel Yoder, Joshua M Staley, Anne P O'Dea, Lauren E Nye, Deepti Satelli, Gregory J Crane, Rashna Madan, Maura F O'Neil, Andrew K Godwin, Harsh Pathak, Qamar J Khan, Joyce O'Shaughnessy, Priyanka Sharma","doi":"10.1016/j.ijrobp.2025.09.038","DOIUrl":"https://doi.org/10.1016/j.ijrobp.2025.09.038","url":null,"abstract":"<p><strong>Purpose: </strong>The radiosensitivity index (RSI) is a validated gene expression-based biomarker that can predict intrinsic radiosensitivity and has been shown to be associated with local control in triple-negative breast cancer (TNBC) patients treated with upfront surgery. Currently, most patients with TNBC receive neoadjuvant systemic therapy (NAST). Whether the RSI predicts response to NAST and how the RSI and predicted radiosensitivity are altered by exposure to NAST is unknown.</p><p><strong>Methods: </strong>Total RNA was extracted from pre-treatment core needle biopsy specimens from 197 TNBC patients treated on the *** (***) and *** (***) trials. Total RNA was also extracted from paired post-NAST (residual disease) tumor tissue on 58 patients. A published algorithm using 10 genes was used to compute the RSI for each tumor. Stromal tumor infiltrating lymphocytes (sTILs) were scored on pre-treatment and post-NAST samples by one expert breast pathologist according to international consensus guidelines. CIBERSORTx was used to impute leukocyte fractions in samples using RNA sequencing data.</p><p><strong>Results: </strong>Cluster analysis of RSI genes in pre-treatment samples revealed immune-depleted (RSI-iD) and immune-enriched (RSI-iE) groups, and this classification was strongly associated with sTIL infiltration (P<0.0001) and likelihood of achieving pathologic complete response (pCR) (P=0.001). RSI showed associations (FDR q<0.01) with M0 and M1 macrophages, CD4+ memory resting, CD4+ memory activated, CD8+, and follicular helper T-cells, activated NK cells, naïve and memory B cells, and resting dendritic cells on CIBERSORTx leukocyte deconvolution. In the entire cohort, NAST-induced change in RSI was variable, but amongst initially RSI-iE tumors that did not achieve pCR, there was a significant decrease in predicted radiosensitivity between paired pre-treatment and post-NAST samples. NAST-induced reduction in sTILs and naïve B cells may be associated with this decrease in radiosensitivity.</p><p><strong>Conclusions: </strong>Pre-treatment RSI cluster identity is associated with the degree of immune enrichment and response to NAST in TNBC. Initially immune-enriched TNBCs that do not achieve a pathologic complete response to NAST exhibit a decrease in predicted radiosensitivity compared to paired pre-treatment tumors.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab combined with chemotherapy and Stereotactic Ablative Body Radiotherapy (SABR) in patients with oligometastatic non-small cell lung cancer: a multi-center phase 2 study.","authors":"Qiwen Li, Honglian Ma, Rongliang Zheng, Ling Cai, Yuan Zhang, Yihong Ling, Fang Peng, Anwen Liu, Hualin Chen, Yong Bao, Yujin Xu, Ming Chen","doi":"10.1016/j.ijrobp.2025.09.045","DOIUrl":"https://doi.org/10.1016/j.ijrobp.2025.09.045","url":null,"abstract":"<p><strong>Purpose: </strong>Immunotherapy plus chemotherapy is the standard of care for driver-gene negative metastatic non-small cell lung cancer (NSCLC). Synchronous oligometastatic disease has a better prognosis than extensive metastasis, and the addition of Stereotactic Ablative Radiotherapy (SABR) results in improved efficacy. However, whether the combination of SABR with immunotherapy and platinum-doublet chemotherapy will lead to long-term disease control or even cure for patients remains unclear.</p><p><strong>Patients and methods: </strong>This was a multi-center, phase 2, single-arm study to evaluate the efficacy and safety of durvalumab in combination with chemotherapy and SABR for oligometastatic stage IV NSCLC without previous systemic therapy. The primary endpoint was investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors Version 1.1.</p><p><strong>Results: </strong>Thirty-five patients were enrolled in the study. Twenty-eight (80%) patients received radiotherapy (RT), including 23 (65.7%) received SABR. The median follow-up time was 24.7 months (95% CI, 21.6-27.5). In the full analysis set (n=35), the median PFS (mPFS) was 10.4 months (95% CI, 4.4-26.1), and the two-year PFS rate and overall survival (OS) rate were 38.5% (95% CI, 21.9-54.8%) and 67.7% (95% CI, 49.0-80.7%), respectively. In the per protocol set (n=32), mPFS was 14.6 months (95% CI, 4.7-26.1), and the two-year PFS rate and OS rate were 42.4% (95% CI, 24.3-59.4%) and 70.8% (95% CI, 51.2-83.8%), respectively. The subgroup analysis showed that the mPFS was 24.3 months (95%CI, 7.6-NE) with SABR vs 3.1 months (95% CI, 1.4-4.7) without SABR (HR, 0.2; 95% CI, 0.09-0.5; P<0.001). Grade 3 or higher treatment related adverse events (TRAEs) and immune-mediated AEs (imAEs) were reported in 57.1% (20/35) and 25.7% (9/35) of patients, respectively.</p><p><strong>Conclusions: </strong>In oligometastatic NSCLC, the combination of durvalumab, chemotherapy and SABR was effective and tolerable. Patients who did not experience disease progression after prior systemic therapy and received SABR might have optimal outcomes.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological Outcomes and Organ Preservation After Brachytherapy for Penile Carcinoma: A Multicentric Retrospective Study by the Brachytherapy Group of the French Society for Radiation Oncology.","authors":"Kanta Ka, Abel Cordoba, Renaud Schiappa, Nicolas Martz, Sophie Espenel, Alexandre Escande, Nicolas Demogeot, Jean Michel Hannoun-Levi, Cyrus Chargari","doi":"10.1016/j.ijrobp.2025.07.052","DOIUrl":"10.1016/j.ijrobp.2025.07.052","url":null,"abstract":"<p><strong>Purpose: </strong>Penile cancer is a rare malignancy with significant implications for patients' quality of life due to the sensitivity of the affected organ. Although partial or total penectomy remains the standard treatment, its functional and psychological sequelae are significant. Brachytherapy is an effective alternative to penectomy offering penile preservation and good local control. This multicenter retrospective study aims to evaluate the oncological outcomes and organ preservation after brachytherapy for localized penile carcinoma.</p><p><strong>Methods and materials: </strong>This study included patients with localized penile carcinoma (T1-T3, N0-N2, and M0) treated across 4 French Cancer Centers. Patients underwent interstitial brachytherapy using low-dose rate, pulse-dose rate, or high-dose rate techniques. Clinical and pathologic data were collected, and survival outcomes were analyzed using Kaplan-Meier methods. Toxicities were assessed per National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.</p><p><strong>Results: </strong>The charts for 408 patients with localized penile cancer, treated with interstitial brachytherapy between 1970 and 2020, were reviewed retrospectively. At a median follow-up of 76 months, the 5-year local control, penile preservation, and overall survival rates were 86% (95% CI, 82.5-90), 85% (95% CI, 81-89), and 82% (95% CI, 78-87), respectively. Acute grade ≥2 toxicities occurred in 34.3%, whereas late urethral stenosis was observed in 18.1%. Circumcision history was associated with a lower risk of acute grade ≥2 toxicities, with odds ratio of 0.115 (95% CI, 0.035-0.376; P < .001). Lymph node involvement emerged as the most significant prognostic factor for disease progression and metastases.</p><p><strong>Conclusions: </strong>This study, the largest to date, confirms the efficacy and safety of brachytherapy as a penis-preserving treatment for localized penile carcinoma. It highlights the importance of lymph node management and multidisciplinary approach, while underlining the need for standardization of protocols to optimize results and limit complications.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Success Lies in the Microscopic Details","authors":"Mona Arbab MD, MEd,&nbsp;Asal Rahimi MD, MS","doi":"10.1016/j.ijrobp.2025.05.002","DOIUrl":"10.1016/j.ijrobp.2025.05.002","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Page 611"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors’ View—FLASH Radiation: A Game-Changer in Pediatric Brain Tumor Treatment?","authors":"Zachary J. Reitman MD, PhD ,&nbsp;Yi Fan PhD","doi":"10.1016/j.ijrobp.2025.04.036","DOIUrl":"10.1016/j.ijrobp.2025.04.036","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages 848-851"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leptomeningeal Metastasis, an Evolving Frontier for Radiation Oncology","authors":"William G. Breen MD ,&nbsp;Rupesh Kotecha MD ,&nbsp;Martin C. Tom MD ,&nbsp;Christoph Straube MD ,&nbsp;Erqi L. Pollom MD, MS ,&nbsp;Christina K. Cramer MD ,&nbsp;Michelle M. Kim MD ,&nbsp;Jonathan T. Yang MD, PhD","doi":"10.1016/j.ijrobp.2025.08.002","DOIUrl":"10.1016/j.ijrobp.2025.08.002","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages 605-609"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARTSCAN: Time to Rethink De-escalation in LA-HNSCC","authors":"Laura Tam MPhil ,&nbsp;Aaron R. Hansen MBBS (Hons)","doi":"10.1016/j.ijrobp.2025.05.081","DOIUrl":"10.1016/j.ijrobp.2025.05.081","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages 691-693"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarva Aathmika Sarvatra: Reflections from the Space of Healing","authors":"","doi":"10.1016/j.ijrobp.2025.05.012","DOIUrl":"10.1016/j.ijrobp.2025.05.012","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages 615-616"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145104158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issue Highlights","authors":"","doi":"10.1016/S0360-3016(25)06099-7","DOIUrl":"10.1016/S0360-3016(25)06099-7","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages A10-A12"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-51 and Omission of Nodal Radiation: One Size Fits All?","authors":"Sachin R. Jhawar MD ,&nbsp;George E. Naoum MD, MMSCI","doi":"10.1016/j.ijrobp.2025.03.087","DOIUrl":"10.1016/j.ijrobp.2025.03.087","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Page 610"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}